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will reduce the morbidity and mortality associated with SDH deficient tumours, 3 there is at present no consensus on when and how surveillance should be performed in children and young adults. Here, we address the question: "What age should clinical, biochemical and radiological surveillance for PPGL be initiated in paediatric SDHx mutation carriers?".
| ME THODS
In order to address this important clinical question, a thorough review of the literature was performed. MEDLINE was searched via
PubMed using the following search terms; (a) SDH or succinate de- 
| What is the prevalence of related disease in childhood SDHx carriers?
Whilst there are several reports of tumour development in pae- A copy number variant was identified in 6 (6.4%) cases (one gene duplication, five exonic deletions and one whole gene deletion).
Notably, the frequency of reported truncating variants (nonsense/ frameshift and splice site variants) identified in this paediatric population was 72% compared to a reported frequency of 52% in an adult population presenting with PPGL. 1 The mean age of this cohort was 13.5 years (range 5-18 years).
There was no significant difference in the mean age at presentation with PPGL in those patients with germline SDHB variants possibility of SDHx mutation penetrance at a young age. However, an appropriate surveillance protocol must balance the occurrence of paediatric tumour development against the increasing evidence that the penetrance of SDHB is lower than originally reported and the potential adverse effects of screening.
2.2 | What are the current recommendations for the age at which to commence surveillance for SDHx mutation carriers?
The Endocrine Society recommends that surveillance should comprise annual biochemistry (urinary or plasma metanephrines) and sporadic cross-sectional imaging of the skull base, neck, thorax, abdomen and pelvis (MRI is the preferred radiation sparing imaging modality). 3 There are no recommendations as to the lower age limit of genetic testing of children in SDHx mutation families. In the UK, genetic testing for inherited neoplasia syndromes is usually conducted around the time when clinical, biochemical and radiological surveillance would begin. 53 It is also important to note that as SDHD 
| What are the controversies and/or risks of early surveillance?
Several factors complicate the decision when surveillance should be commenced in paediatric SDHx mutation carriers. Important considerations include the growing awareness that the lifetime penetrance of SDHB mutations is significantly lower (see above) than that estimated when the gene was first identified (originally estimated at 70%-80%).
In addition, surveillance programmes can be disruptive to patients' placed MRI imaging with ultrasound in children under 10 years of age if they were unable to tolerate MRI. In doing so, the patients could experience the potential benefits of earlier surveillance whilst minimizing the anxiety involved during surveillance. However it must also be considered that ultrasound has a lower sensitivity and specificity compared with MRI in PPGL detection.
3
The Endocrine Society clearly state that the morbidity associated with SDHB gene mutations requires particular attention, 3 and therefore, more stringent screening efforts may be necessary in order to reduce the morbidity and mortality associated with SDHBmutated PPGL. It is notable that in the paediatric population studied 
| CON CLUS ION
Despite the occurrence of SDHx driven tumours in children, the majority of these tumours present in adulthood. The absolute risks 
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